Skip to main content

AstraZeneca plc (AZN)

NASDAQ: AZN · Delayed Price · USD
58.85
+0.35 (0.60%)
Pre-market:Sep 21, 2021 7:24 AM EDT
58.50
2.94 (5.29%)
At close: Sep 20, 4:00 PM
Market Cap181.45B
Revenue (ttm)29.53B
Net Income (ttm)3.77B
Shares Out3.10B
EPS (ttm)1.44
PE Ratio40.75
Forward PE16.50
Dividend$1.39 (2.38%)
Ex-Dividend DateAug 12, 2021
Volume16,596,512
Open56.16
Previous Close55.56
Day's Range56.08 - 58.60
52-Week Range46.11 - 60.45
Beta0.20
AnalystsBuy
Price Target62.99 (+7.7%)
Est. Earnings DateNov 12, 2021

About AZN

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico...

IndustryPharmaceuticals
IPO DateMay 12, 1993
CEOPascal Soriot
Employees76,100
Stock ExchangeNASDAQ
Ticker SymbolAZN
Full Company Profile

Financial Performance

In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 62.99, which is an increase of 7.67% from the latest price.

Price Target
$62.99
(7.67% upside)
Analyst Consensus: Buy

News

AstraZeneca To Inject $360M In Irish API Manufacturing Site

AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The planned investment at the Alexion Campus in...

38 minutes ago - Benzinga

Here's Why Everyone's Talking About AstraZeneca Right Now

The company's next-generation treatment for breast cancer could become the new standard of care.

1 hour ago - The Motley Fool

AstraZeneca to invest $360 million in Irish drug manufacturing site

(Reuters) -AstraZeneca said on Tuesday it would invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or the main components of medicines.

4 hours ago - Reuters

Breakthrough AstraZeneca Breast Cancer Drug Massively Reduces Disease and Fatalities in Trial

If all AstraZeneca did in the last year was team with Oxford University in a heroic quest to design, test, and deliver in record time one of the.

9 hours ago - The Motley Fool

Why AstraZeneca and Surface Oncology Rose Today

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

Other symbols:SURF
14 hours ago - The Motley Fool

AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests.  What Happened: The Phase 3 DESTINY-...

15 hours ago - Benzinga

Why AstraZeneca Shares Are Trading Higher Today

AstraZeneca PLC (NASDAQ: AZN) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progres...

18 hours ago - Benzinga

AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data

AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus either carboplatin or cisplatin. The I...

19 hours ago - Benzinga

AstraZeneca's EVP on the potential of the pharma giant's new breast cancer drug

AstraZeneca Executive Vice-President of the Oncology Business Unit David Frederickson discusses the drugmaker's Enhertu breast cancer drug trial results.

20 hours ago - CNBC International TV

AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial include...

3 days ago - Benzinga

2 Pharma Stocks You Can Buy and Hold for the Next Decade

Both stocks have grabbed plenty of headlines over the past year.

Other symbols:PFE
4 days ago - The Motley Fool

Got $3,000? Keep It Safe With These 3 Healthcare Stocks

They offer products that their customers absolutely can't do without, and they also pay dividends.

Other symbols:ABTARE
1 week ago - The Motley Fool

3 No-Brainer Stocks to Invest $100 in Right Now

You don't need a giant pile of cash to generate a healthy return from this trio of growth, value, and income stocks.

Other symbols:BARKNLY
1 week ago - The Motley Fool

A Look at R&D Spending in Pharma

In GAAP accounting, fixed assets are usually capitalized on a company's balance sheet and subsequently amortized over their expected useful life.

Other symbols:GSKJNJMRKNVSPFE
1 week ago - GuruFocus

AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals

AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.

1 week ago - Zacks Investment Research

Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?

Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.

Other symbols:JNJMRNAPFE
1 week ago - Zacks Investment Research

AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings

POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer patients. The combo therapy topped overall su...

1 week ago - Benzinga

AstraZeneca's Two Asthma Trials Meet Primary Endpoints

Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of albuterol and budesonide developed ...

1 week ago - Benzinga

European Medicines Agency Lists Nerve Disorder As “Very Rare” Side Effect Of AstraZeneca Covid-19 Vaccine

The incidence of the side effect remains extremely rare with only 833 cases being reported worldwide from about 592 million administered doses of the AstraZeneca vaccine.

1 week ago - Forbes

EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots

The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE: JNJ) and AstraZeneca plc (NASDAQ: AZN) to reflect several n...

1 week ago - Benzinga

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.

Other symbols:JNJPFE
1 week ago - Zacks Investment Research

AstraZeneca's (AZN) Ultomiris Gets EU Nod for Rare Disease in Kids

AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.

2 weeks ago - Zacks Investment Research

Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx

Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.

Other symbols:TMO
2 weeks ago - Zacks Investment Research

AstraZeneca Enters Another Major Market With This Indication

The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.

2 weeks ago - The Motley Fool

AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents

The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above) and adolescents. Alexion became a part ...

2 weeks ago - Benzinga